Y-mAbs Therapeutics (NASDAQ:YMAB) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ FY2023 earnings at ($0.65) EPS, Q1 2024 earnings at ($0.19) EPS, Q2 […]

Related Keywords

United States , ,Acadian Asset Management ,Avestar Capital ,Morgan Stanley ,Y Mabs Therapeutics Inc ,Connor Clark Lunn Investment Management Ltd ,Rice Hall James Associates ,Jpmorgan Chase Co ,Canaccord Genuity Group ,Y Mabs Therapeutics ,Free Report ,Y Mabs Therapeutic ,Genuity Group ,Abs Therapeutics ,Asset Management ,Lunn Investment Management ,Hall James ,Get Free Report ,Y Mabs Therapeutics Daily ,Nasdaq Ymab ,Kymab ,Medical ,Reiterated Rating ,Hc Wainwright ,